Summary of Heron Therapeutics Q2 2026 Earnings Call

1Key Financial Results and Metrics

Net Revenue: $37.7 million for Q2 2026, up from $34.7 million in Q1 2026 but slightly below expectations.

Gross Margin: 69.3%.

Operating Loss: $2 million; Net Loss: $5.5 million, compared to a net loss of $2.4 million in Q2 2025.

Adjusted EBITDA: $3.2 million, an increase from $2.2 million in the prior year.

Cash Position: $42.7 million in cash, cash equivalents, and short-term investments, with pro forma cash of approximately $28.5 million after debt payments.

2Strategic Updates and Business Highlights

Product Performance:

CINVANTI: Revenue of $21.8 million, up from $20.5 million in Q1 but down year-over-year due to increased competition.

ZYNRELEF: Revenue of $11.1 million, a 9% increase from Q1 but below expectations; average daily units grew 19% year-over-year.

APONVIE: Revenue of $4.2 million, up 74% year-over-year, capturing a 23% share of the surgical NK-1 segment.

Balance Sheet Management: Amended credit facility with Hercules to reset covenants through 2027 and reduce principal by $17.5 million.

Cost Control: Paused planned sales force expansion and tightened spending in response to a recent court ruling affecting CINVANTI.

3Forward Guidance and Outlook

Withdrawal of Full-Year Guidance: The company withdrew its previous guidance of $173 million to $183 million in net product sales and $10 million to $20 million in adjusted EBITDA due to uncertainties surrounding the CINVANTI generic competition, changes in spending plans, and ongoing strategic evaluations.

Future Reporting: Will provide updates on cash position, spending, and covenant compliance quarterly instead of annual guidance.

4Bad News, Challenges, or Points of Concern

CINVANTI Competition: Facing potential generic competition, which could significantly impact sales; the timing and terms of any launch remain uncertain.

ZYNRELEF Underperformance: Sales growth was below expectations, attributed to slower market recovery and execution challenges.

Market Dynamics: General macroeconomic factors may be affecting surgical volumes and healthcare spending, although the company did not report significant impacts.

5Notable Q&A Insights

Debt Covenants: Management expressed confidence in meeting updated debt covenants, even if a generic CINVANTI enters the market, citing conservative modeling of the launch timeline.

ZYNRELEF Performance: The underperformance was acknowledged as an execution issue rather than product-related, with expectations for recovery in the latter half of the year.

CINVANTI Settlements: Clarified that potential launches of generics would not affect existing settlement agreements with other players. Overall, while Heron Therapeutics showed some positive growth in certain product lines, significant challenges loom with competitive pressures on CINVANTI and execution hurdles for ZYNRELEF. The company is taking proactive measures to manage its financial health amidst these uncertainties.